Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
GMM Pfaudler US completes acquisition of MixPro
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
Covaris is a global leader in the development and deployment of end-to-end solutions for high-throughput genomic and proteomic analysis
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
India had proposed for setting up the global standards for millets
The product has been in-licensed from Strides and will be commercialized by Amneal
Subscribe To Our Newsletter & Stay Updated
